Please login to the form below

Not currently logged in
Email:
Password:

adverse events

This page shows the latest adverse events news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana first SGLT2 to show kidney disease benefits

J&J’s Invokana first SGLT2 to show kidney disease benefits

The drug also reduced the risk of cardiovascular (CV) death and hospitalisation for heart failure by 31%, major adverse CV events by 20%, and the risk of hospitalisation for heart failure

Latest news

More from news
Approximately 4 fully matching, plus 302 partially matching documents found.

Latest Intelligence

  • China’s clinical trial shake-up China’s clinical trial shake-up

    Investigators and sponsors are also subject to rules about the reporting of adverse events. ... When a serious adverse event occurs, the investigator must inform the sponsor, ethics committee and the National Medical Products Administration (NMPA).

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    action.”. Adverse events and autoimmunity. Another major challenge for all immunotherapy studies, including combined immunotherapy trials, is the increased potential for autoimmunity. ... The risk of autoimmune responses or toxicities, and indeed all

  • How pharma can unlock the potential of influencer marketing How pharma can unlock the potential of influencer marketing

    Either way, ensure you have a social playbook in place outlining who is responsible for social media monitoring and how you will respond should any adverse events or inappropriate comments occur

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Conventional stem cell transplants cost anywhere between $500, 000 and $1m, while also carrying the risk of having to treat adverse events such as gvhd for example.

  • A new era of smart pharma A new era of smart pharma

    Remote monitoring has its place but sponsors must still be able to collect detailed information on clinical endpoints, serious adverse events (SAEs) and events of special interest. ... SAEs). It is in this area that pharmacovigilance, the science

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics